کوینجێسترۆن

کوینجێسترۆن ھەروەھا بە (progesterone 3-cyclopentyl enol ether (PCPE)ـش ناسراوة، لەژێر ناوی بازرگانی (ئینۆل لوتیۆڤیس Enol-Luteovis) دا دەفرۆشرێت، دەرمانێکی پرۆجستینە کە پێشوو تر بۆ کۆنتڕۆلی دووگیانی بەکاردەھات لە ئیتاڵیا بەڵام چیتر ناخرێتە مارکێتەکانەوە^[١]^[٢]^[٣]^[٤]^[٥] لە ڕێگەی دەمەوە بەکاردێت^[٦]

سەرچاوەکان

^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1058. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2085-3. OCLC 898564124. {{cite book}}: نرخەکانی ڕێکەوت بپشکنە لە: |date= (یارمەتی)
^ International Planned Parenthood Federation. Medical Committee. Oral Advisory Group (1965). Handbook on oral contraception. Little, Brown. p. 18. OCLC 2717593.
^ Larrey D، Geneve J، Pessayre D، Machayekhi JP، Degott C، Benhamou JP (1987). «Prolonged cholestasis after cyproheptadine-induced acute hepatitis». J. Clin. Gastroenterol. 9 (1): 102–4. doi:10.1097/00004836-198702000-00026. ISSN 0192-0790. PMID 3559100. She had been taking an oral contraceptive combining ethinylestradiol and quingestrone since 1980.
^ Denis Frank Hawkins (1974). Obstetric therapeutics: clinical pharmacology and therapeutics in obstetric practice. Baillière Tindall. pp. 129, 138, 145. ISBN 978-0-7020-0471-1.
^ P. J. Bentley (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 274–. ISBN 978-0-521-22673-8.
^ Current Medicine and Drugs. 1962. ISSN 0590-4048. Enol Luteovis (3 cyclo-pentyl enol ether of progesterone) is the only oral progestin producing pregnanediol as a metabolite. It is not very potent and probably carries very little risk of producing virilizing effects on a female foetus. Thus it is more closely related to progesterone than the other synthetic progestins.

دەروازەی زانست

[Elks2014-1] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1058. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2085-3. OCLC 898564124. {{cite book}}: نرخەکانی ڕێکەوت بپشکنە لە: |date= (یارمەتی)

[Group1965-2] International Planned Parenthood Federation. Medical Committee. Oral Advisory Group (1965). Handbook on oral contraception. Little, Brown. p. 18. OCLC 2717593.

[pmid_3559100-3] Larrey D، Geneve J، Pessayre D، Machayekhi JP، Degott C، Benhamou JP (1987). «Prolonged cholestasis after cyproheptadine-induced acute hepatitis». J. Clin. Gastroenterol. 9 (1): 102–4. doi:10.1097/00004836-198702000-00026. ISSN 0192-0790. PMID 3559100. She had been taking an oral contraceptive combining ethinylestradiol and quingestrone since 1980.

[Hawkins1974-4] Denis Frank Hawkins (1974). Obstetric therapeutics: clinical pharmacology and therapeutics in obstetric practice. Baillière Tindall. pp. 129, 138, 145. ISBN 978-0-7020-0471-1.

[Bentley1980-5] P. J. Bentley (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 274–. ISBN 978-0-521-22673-8.

[CurrentMedicineAndDrugs1962-6] Current Medicine and Drugs. 1962. ISSN 0590-4048. Enol Luteovis (3 cyclo-pentyl enol ether of progesterone) is the only oral progestin producing pregnanediol as a metabolite. It is not very potent and probably carries very little risk of producing virilizing effects on a female foetus. Thus it is more closely related to progesterone than the other synthetic progestins.

[١]

[٢]

[٣]

[٤]

[٥]

[٦]